The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Merck
Combining chemotherapy and programmed death 1 (PD-1) blockade to induce a T-cell response in patients with metastatic triple negative breast cancer (mTNBC).
 
Elias Obeid
Honoraria - Guidepoint Global; LEK
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Genentech; Merck
 
Chun Zhou
Research Funding - Merck
 
Alexander Macfarlane
Research Funding - Horizon Pharma; Merck
 
R. Katherine Alpaugh
No Relationships to Disclose
 
Cecilia McAleer
Research Funding - Merck
 
Essel Dulaimi
No Relationships to Disclose
 
Kerry Campbell
Honoraria - Bristol-Myers Squibb; Janssen
Research Funding - Bristol-Myers Squibb; Horizon Pharma; NantWorks
Patents, Royalties, Other Intellectual Property - NantWorks
 
Lori J. Goldstein
Honoraria - Genentech; Glenmark; Pfizer; Puma Biotechnology; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Dompé Farmaceutici; Genentech; Merck; Pfizer; Puma Biotechnology; Roche Pharma AG
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Other Relationship - Roche Pharma AG